Arrayit Corporation (OTCBB: ARYC), a proprietary life sciences technology leader, announces that on September 11th, 2009, on the eighth anniversary of the World Trade Center attacks, the company won a competitive bid from the Centers for Disease Control in Atlanta, Georgia to manufacture devices designed to combat global bioterrorism.
The CDC will deploy Arrayit's proprietary peptide microarray manufacturing platform to create microarrays designed to decipher and combat infectious agents that pose a lethal threat in terrorist attacks. Peptide microarrays are analytical devices that allow scientists to rapidly map the topology of protein molecules that confer infectivity by infectious bioterrorist agents.
"We are pleased to be selected by the CDC for this competitive government contract," states Rene Schena, CEO and co-founder of Arrayit Corp. "We look forward to leveraging the unique capabilities of our patented microarray platform to improve homeland security."
LGM Pharma unveils enhanced analytical testing services and expands CDMO portfolio with additional suppository manufacturing capabilities